Shots:

• NeuroLucent will receive an upfront along with additional payments upon the achievement of milestones. The companies collaborated to accelerate search for a therapeutic candidate
• PostEra will use its ML technology to optimize NeuroLucent’s lead compounds through a series of design make test cycles that has previously been shown to accelerate medicinal chemistry campaigns
• PostEra will also deploy its Manifold platform- providing access to compounds through a WW network of vendors and CROs

 ­ Ref: PRNewswire | Image: LinkedIn